Valgen Medical Technology Files IPO Prospectus Following 2020 China Unicorn Recognition

Recently, Valgen Medtech was listed on the 2020 China Unicorn Enterprise List. The total valuation of Chinese unicorn enterprises in 2020 reached $1.47 billion. Hot sectors for financing included internet education, new energy and intelligent vehicles, innovative drugs and medical devices, and viral consumer products. Among these, the innovative drugs and medical devices sector emerged as the top choice for investment. Valgen Medtech ranked sixth in the innovative drugs and medical devices category, marking its first appearance on the list.

Valgen Medtech, driven by innovation, focuses on the research and development of treatment technologies for structural heart disease, particularly those related to the mitral and tricuspid valves, progressively enhancing its comprehensive product portfolio for valve repair therapies.

The company’s core products at this stage mainly include: the MitralStitch mitral valve repair system, the DragonFly transfemoral mitral valve clip system, and the DragonFly transfemoral tricuspid valve clip system. Among these, the MitralStitch mitral valve repair system is China’s first transapical interventional therapy technology, providing the latest minimally invasive treatment options for patients with complex and critical conditions.

Technology Drives the Future, Innovation Fuels Development: Valgen Medtech adheres to its corporate strategy of being rooted in China and embracing the world, further accelerating the development and commercial application of minimally invasive and precise interventional diagnostic and therapeutic technologies, while continuously providing physicians and patients with innovative solutions for various valve repair procedures.

Unicorn companies are startups characterized by rapid growth, scarcity, explosive expansion, and disruptive innovation. In 2020, the number of unicorn companies in China reached 251, spanning 27 industry sectors. Compared with the sector distribution of unicorns in the previous four periods, the biopharmaceutical, innovative drugs and medical devices, and digital health sectors have benefited from the COVID-19 pandemic and favorable policies, leading in the number of newly financed companies and listed enterprises, and attracting significant capital interest. Unicorn companies have achieved remarkable success in pioneering new business models and opening up new market sectors.